Cancer treatment just got faster: FDA approves Genentech’s Tecentriq Hybreza for quick 7-minute injection

Pallavi Madhiraju- September 13, 2024

The U.S. Food and Drug Administration (FDA) has granted approval for Tecentriq Hybreza, the first and only PD-(L)1 inhibitor for subcutaneous injection, developed by Genentech, ... Read More

Genentech announces reintroduction of Susvimo for Wet AMD treatment in US

Pallavi Madhiraju- July 8, 2024

Genentech, a key member of the Roche Group, has officially announced the reintroduction of Susvimo (ranibizumab injection) 100 mg/mL, a cutting-edge treatment for wet, or ... Read More

FDA approves Genentech’s Vabysmo prefilled syringe for eye diseases

Pallavi Madhiraju- July 5, 2024

In a significant advancement in the treatment of eye diseases, the U.S. Food and Drug Administration (FDA) has approved Genentech's Vabysmo (faricimab-svoa) 6.0 mg single-dose ... Read More

Lonza to acquire Genentech’s biologics manufacturing facility in Vacaville for $1.2bn

Pallavi Madhiraju- March 20, 2024

In a strategic move that significantly escalates its capacity in the biologics manufacturing landscape, Lonza, a key global player in manufacturing for the pharmaceutical, biotech, ... Read More

FDA approves Genentech’s Xolair for food allergies: A new horizon in allergy treatment

Pallavi Madhiraju- February 17, 2024

The U.S. Food and Drug Administration (FDA) has approved Xolair (omalizumab) for reducing allergic reactions, including anaphylaxis, that may occur with accidental exposure to foods ... Read More

Genentech’s Phase 3 study of inavolisib in breast cancer reveals positive results

Pallavi Madhiraju- December 9, 2023

Genentech, part of the Roche Group, has presented compelling results from the Phase III INAVO120 study, evaluating the effectiveness of inavolisib in combination with palbociclib ... Read More

Genentech’s Alecensa shows promise in Phase III ALINA study for early-stage ALK-positive NSCLC

Pallavi Madhiraju- September 3, 2023

Genentech, a Roche Group member, has announced positive results from its Phase III ALINA study evaluating Alecensa (alectinib), setting a new standard for treating early-stage ... Read More

Genentech bags Lunsumio FDA approval for R/R follicular lymphoma

Raghuram Kadari- December 28, 2022

Lunsumio FDA approval : Genentech, a subsidiary of the Roche Group, has secured the approval of the US Food and Drug Administration (FDA) for Lunsumio ... Read More

Genentech gets Actemra FDA approval for COVID-19 in hospitalized adults

Raghuram Kadari- December 26, 2022

Actemra FDA approval : Genentech, a subsidiary of Roche, has received the approval of the US Food and Drug Administration (FDA) for Actemra (tocilizumab) intravenous ... Read More

FDA accepts BLA for Lucentis referencing ophthalmology biosimilar SB11

pharmanewsdaily- November 19, 2020

Samsung Bioepis and Biogen said that the US Food and Drug Administration (FDA) has accepted for review the biologics license application for SB11, a proposed ... Read More